Palisade Bio (Palisade Bio) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Palisade Bio's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Palisade Bio's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $10.20.

Palisade Bio Accounts Receivable Historical Data

The historical data trend for Palisade Bio's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio Accounts Receivable Chart

Palisade Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

0.06

Palisade Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial											0.25	-	-	-	-

Palisade Bio Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Palisade Bio Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Palisade Bio's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Palisade Bio's accounts receivable are only considered to be worth 75% of book value:

Palisade Bio's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(11.276	+	0.75 * 0	+	0.5 * 0	-	2.588
-	0.002	-	0)	/	0.8513
=	10.20

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Palisade Bio Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Palisade Bio's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Palisade Bio (Palisade Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (NAS:PALI) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

7NS:Germany

Address

5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008

Website

https://www.palisadebio.com

Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Executives

Donald Allen Williams	director	C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
John David Finley	officer: Chief Financial Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Robert J. Trenschel	director	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Mitchell Lawrence Jones	officer: Chief Medical Officer	70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907
Robert Curtis Mcrae	officer: Chief Operating Officer	675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075
Thomas Hallam	director, officer: Chief Executive Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Michael John Dawson	officer: Chief Medical Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Yuma Regional Medical Center	10 percent owner	2400 S AVENUE A, YUMA AZ 85364
Stephanie Diaz	director	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
James R Neal	director	2910 SEVENTH STREET, BERKELEY CA 94710
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
David J Mazzo	director	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Binxian Wei	director	P.O. BOX 2231, LIVINGSTON NJ 07039
Kenneth C Carter	director, officer: Executive Chairman	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Cristina Csimma	director	14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142